We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
Next-generation wellbeing analytics for individuals and organisations – boosts happiness and productivity
days to go: Expired investment: £768,597
BeneTalk is an innovative digital therapeutic solution, providing on-demand support to individuals who stutter and their families, aiming to enhance their quality of life and confidence. Stuttering affects millions globally, and with limited specialized therapy options, BeneTalk addresses accessibility challenges by offering timely assistance, aiming to mitigate the higher risk of low self-esteem and mental health issues faced by individuals who stutter and their families.
days to go: Expired investment: £173,123
Clinical Net is a health-tech firm focused on revolutionizing access to innovative clinical trials. Their AI platform swiftly connects patients with suitable trials, addressing the challenge of low participation rates and delays that hinder pharmaceutical research. With over 69,000 trials globally, their solution aims to streamline the cumbersome and time-consuming process of trial matching, making it more efficient and accessible within 5 minutes. This innovative approach targets the $3.73 billion patient recruitment market while ensuring individuals have easier access to groundbreaking treatments.
days to go: Expired investment: £136,827
Bright Salon is a smartphone app that is designed to allow hair and beauty salons grow their business. The app can be used to fill in the gaps from last minute cancellations. The app can also be used as an alternative to paper-based loyalty schemes. Using the app for a loyalty scheme allows customers to see exactly how many points they have and the milestones they have to reach to acheive certain rewards.
days to go: Expired investment: £28,640
Pretty Athletic offers award-winning skincare solutions for athletic and active women. It makes high-performance, effective, and natural skin-care solutions for active women who sweat and experience exercise-related skincare problems. In 2018, the company's product Workout Glow was awarded the Pure Beauty Gold award for Best New Natural Face Product. It has now sold more than 15,000 units since its launch. Pretty Athletic has also collaborated with many brands such as Paola's Body Barre and Lululemon. With the proceeds, the company will intend to improve its Research & Development, Sales, and Packaging.
days to go: Expired investment: £62,748
HealthBox Software is a technology company building products for the post-COVID healthcare landscape. Its first product, ClearPass, was met with success. The tool asks an employee a series of screening questions related to COVID-19, including evidence of fever, fatigue, and dry cough, etc. ClearPass has over 400,000 end-users including companies like Johnson Controls, Remy Cointreau and the San Diego School District. HealthBox aims to be a significant contender in the global digital health market that is expected to be worth $600 billion by 2026. The company is on the verge of launching another innovative product, MyHealthBox. It is a consumer-facing digital health app that will allow users to store their medical records, easily accessible 24/7. HealthBox asserts that the app will have an array of features, including AI health assessment services, dietary advice and data-powered lifestyle guidance. The company will use 47% of the investment towards technology and development costs, and 53% towards sales and marketing.

Pitch Rated

79%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £144,265
Byrd is a coaching platform that works around everyday life to keep people running. It asserts that its unique EQAI-coach uses 1 billion variables to coach people to their goal, whether that’s simply to remain healthy or to hit a specific event. The company estimates that 200 million people were running globally in 2018. It seeks to target this group and become a contender in a fitness market that is estimated to be worth $2.4 billion. The company has created and tested two beta versions of its Android and iOS apps. It points out that it has conducted surveys involving hundreds of runners clocking in 20,000 km of running and incorporated that data into its portal. Byrd argues that its app has been built on Google Cloud infrastructure and is ready to horizontally scale. It will use 40% of the investment in product evolution, 20% in acquisition, 23% towards marketing, and 17% towards enriching customer experience.
days to go: Expired investment: £266,836
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph